Clinical trials: Olanzapine, completed
COVID-19 Vaccine Adverse Reaction
Detoxification From the Lipid Tract
Apart from electroencephalogram biofeedback and electrical brain stimulation adopted for maintenance treatment, the study utilizes ultra-low frequency transcranial magnetic stimulation (ULF-TMS) for initial γ-aminobutyric acid…
- Trial name
- NCT06357104
- Testing
- electroencephalogram biofeedback, electrical brain stimulation, ultra-low frequency transcranial magnetic stimulation
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Pachankis, Yang I., M.D.
Schizophrenia
Effectiveness of Antipsychotic Combination With Psychosocial Intervention on Outcome of Patients With Schizophrenia
Antipsychotic alone is limit to improve the overall outcome of schizophrenia and has a high discontinue rate.To solve these problems, we provide practical and available psychosocial intervention.
- Trial name
- ACPIOS (NCT00654576)
- Testing
- Chlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripitrazole, psychosocial intervention
- Where
- China
- Volunteers
- 1,400 people
- Sponsor
- Central South University
Anorexia Nervosa
Olanzapine in the Treatment of Anorexia Nervosa
This study compared 10 weeks of treatment with olanzapine versus placebo in adolescent females with anorexia nervosa-restricting type who were undergoing acute treatment on an inpatient unit or a day hospital program that…
- Trial name
- NCT00592930
- Testing
- olanzapine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Northwell Health
Stroke
A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group
The purpose of this study is to extend the recent Food and Drug Administration (FDA) Sentinel tabulations regarding stroke risk among new users of typical and atypical antipsychotics to participants who were aged 18-64 years and…
- Trial name
- NCT04002700
- Testing
- Haloperidol, Typical Antipsychotics, Atypical Antipsychotics
- Where
- United States
- Volunteers
- 1,234,412 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia
The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With Schizophrenia
A randomized, double-blind trial of the treatment effect of dose-low antipsychotics combined with low-dose sertraline in 1640 schizophrenia patients
- Trial name
- NCT04076371
- Testing
- olanzapine-sertraline combination, only olanzapine, risperidone-sertraline combination
- Volunteers
- 1,640 people
- Sponsor
- Beijing HuiLongGuan Hospital
Bipolar Disorder, Schizoaffective Disorder
Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features
Aim: In a population of first episode manic patients with psychotic features, we want to compare the side effect profile, the degree of adherence and the subjective well being, as well as the efficacy of two treatments: The…
- Trial name
- NCT00202293
- Testing
- Olanzapine, Lithium, Chlorpromazine
- Where
- Australia
- Volunteers
- 83 people
- Sponsor
- Melbourne Health
Schizophrenia
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
Evaluate the clinical outcome of two switching strategies to iloperidone treatment in adult subjects with schizophrenia who require a change in their current antipsychotic treatment of risperidone, olanzapine, or aripiprazole due…
- Trial name
- i-FANS (NCT01207414)
- Testing
- iloperidone
- Where
- 59 sites in United States
- Volunteers
- 501 people
- Sponsor
- Novartis
Schizophrenia, Bipolar Disorder
Olanzapine Treated Adolescents With Schizophrenia or Bipolar I Disorder
The purpose of this study is to characterize olanzapine pharmacokinetics: the inter- and intra- subject variabilities of olanzapine pharmacokinetics; and the potential influence of patient factors such as age, weight, gender…
- Trial name
- NCT00113594
- Testing
- Olanzapine
- Where
- 17 sites in United States, Puerto Rico and 1 more
- Volunteers
- 100 people
- Sponsor
- Eli Lilly and Company
Schizophrenia
Study Comparing the Affect of Bifeprunox Vs Olanzapine on Weight During the Treatment of Outpatients With Schizophrenia.
This study will compare bifeprunox to a currently marketed medication, Zyprexa (olanzapine), with respect to the affect on weight during the treatment of outpatients with schizophrenia.
- Trial name
- NCT00380224
- Testing
- bifeprunox, olanzapine
- Where
- 67 sites in United States
- Volunteers
- 120 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Complete Response Rate to Chemotherapy-induced Nausea and Vomiting Prophylaxis
Olanzapine for Chemotherapy-induced Nausea and Vomiting Prophylaxis
To investigate that olanzapine can reduced side effect about nausea and vomiting in women with gynecologic cancers receiving carboplatin-based regimen by using olanzapine and placebo
- Trial name
- OLN-EME (NCT04232423)
- Testing
- Olanzapine 10 Mg ORAL TABLET, Olanzapine 5 Mg ORAL TABLET
- Where
- Thailand
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Department of Medical Services Ministry of Public Health of Thailand
Schizophrenia
Atypical Antipsychotic Treatment Effect On Brain Function In Schizophrenia Measured By FMRI
The general aim is to compare the effects of typical and atypical antipsychotic medication on brain structure and function. A parallel group treatment trial will be utilized to compare the effects of the typical antipsychotic…
- Trial name
- NCT01234454
- Testing
- Risperidone, Olanzapine
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Weight Gain
A Study on Induced Weight Gain During Atypical Antipsychotic Treatment and Its Management With Psychoeducational Programme
Olanzapine is an atypical antipsychotic agent indicated for the treatment of schizophrenia and moderate to severe manic episode. Olanzapine is among the many antipsychotic agents associated with weight gain .
- Trial name
- NCT00191828
- Testing
- olanzapine
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Eli Lilly and Company
Schizophrenia, Schizoaffective Disorder
Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and Quetiapine
Weight gain is a serious, common side effect of many antipsychotic medications. On average, the highest amounts of weight gain are found to occur in people taking clozaril and olanzapine, but with significant weight gain occuring…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Mood Disorders
- Trial name
- NCT00312598
- Testing
- Aripiprazole
- Volunteers
- 30 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia
Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)
This study is a sequential multiple-assignment randomized trial (RCT) of antipsychotic medication treatment in first-episode schizophrenia patients in the real-world settings.Through analysis of treatment efficacy rate and…
- Trial name
- NCT03510325
- Testing
- Phase 1: Olanzapine, Phase 1: Risperidone, Phase 1: Amisulpride
- Where
- 7 sites in China
- Volunteers
- 762 people
- Sponsor
- Shanghai Mental Health Center
Childhood Schizophrenia, Psychotic Disorder
Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
The purpose of this study is to compare the effectiveness and side effects of the drugs clozapine and olanzapine in children and adolescents with schizophrenia and psychoses.
- Conditions
- Childhood Schizophrenia, Psychotic Disorder, Schizophrenia
- Trial name
- NCT00001656
- Testing
- Olanzapine, Clozapine
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Mental Health (NIMH)
Bipolar I Disorder, Schizophrenia
Study in Adolescents With Schizophrenia or Bipolar Disorder
Open-label safety study of oral olanzapine treatment in adolescents, aged 13 to 17 years, with bipolar I disorder (manic or mixed episodes) or schizophrenia.
- Trial name
- NCT00982020
- Testing
- Olanzapine, Standard behavioral weight intervention, Intense behavioral weight intervention
- Where
- 14 sites in United States, Poland and 2 more
- Volunteers
- 203 people
- Sponsor
- Eli Lilly and Company
Schizophrenia
Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism
This is a Phase 4, randomized, open-label, parallel group study designed to assess the clinical and biological effects of 12 months of treatment with long acting intramuscular (IM) aripiprazole (Abilify®) as measured by clinical…
- Trial name
- NCT02237417
- Testing
- Standard of Care Oral antipsychotics, IM aripiprazole once monthly, No Treatment
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- University of Utah
Schizophrenic Disorders
Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia
This is a randomized, double-blind study to determine how well intramuscular (IM) olanzapine depot works compared to oral olanzapine; evaluate the safety and tolerability of IM olanzapine depot compared to oral olanzapine…
- Trial name
- NCT00088491
- Testing
- Intramuscular Olanzapine Depot, Oral Olanzapine
- Where
- 4 sites in Finland, Turkey (Türkiye)
- Volunteers
- 1,205 people
- Sponsor
- Eli Lilly and Company
Chemotherapy Induced Nausea and Vomiting
Pilot Study of Olanzapine and Aprepitant to Prevent Nausea and Vomiting in Children Receiving Chemotherapy
The purpose of this study is to determine the feasibility of a larger trial comparing olanzapine and aprepitant and to obtain preliminary data on the effectiveness of these two medications to treat nausea and vomiting in children…
- Trial name
- NCT02097823
- Testing
- Olanzapine, Aprepitant
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Indiana University
Chemotherapy-induced Nausea and Vomiting
Olanzapine or Dexamethasone, With 5-HT3 RA and NK-1 RA, to Prevent CINV
Chemotherapy-induced nausea and vomiting is a common side effect of cancer treatments, and dexamethasone offers a clear advantage over placebo for protection against chemotherapy-induced emesis in both acute and delayed phases.
- Trial name
- NCT04437017
- Testing
- Olanzapine+NK-1 RA+5-HT3 RA, Dexamethasone+NK-1 RA+5-HT3 RA
- Where
- China
- Volunteers
- 557 people
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University